Home LiteratureArticle Details
PMID: 20432533 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Nature ·Vol. 464 ·No. 7293 ·2010-04-29 ·Pages 1293-300

Bluestone JA, Herold K, Eisenbarth G

Abstract

Type 1 diabetes is an autoimmune disorder afflicting millions of people worldwide. Once diagnosed, patients require lifelong insulin treatment and can experience numerous disease-associated complications. The last decade has seen tremendous advances in elucidating the causes and treatment of the disease based on extensive research both in rodent models of spontaneous diabetes and in humans. Integrating these advances has led to the recognition that the balance between regulatory and effector T cells determines disease risk, timing of disease activation, and disease tempo. Here we describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies.

MeSH Terms
Animals Diabetes Mellitus, Type 1/genetics,physiopathology,prevention & control,therapy Humans
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Bluestone Jeffrey A
Diabetes Center and the Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA. jbluest@diabetes.ucsf.edu
Herold Kevan
Eisenbarth George
References (86)
86 references, click to expand
  1. Extracellular redox modulation by regulatory T cells.
    Nat Chem Biol. 2009 Oct;5(10):721-3 PMID: 19718041
  2. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function.
    J Immunol. 2009 Jul 1;183(1):75-82 PMID: 19535634
  3. On the pathogenicity of autoantigen-specific T-cell receptors.
    Diabetes. 2008 May;57(5):1321-30 PMID: 18299317
  4. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice.
    Diabetes. 2005 Sep;54(9):2596-601 PMID: 16123347
  5. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.
    Nat Immunol. 2009 Jul;10(7):689-95 PMID: 19536194
  6. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.
    J Clin Endocrinol Metab. 2008 Oct;93(10):4065-74 PMID: 18664535
  7. Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes.
    Diabetologia. 2006 Jul;49(7):1512-21 PMID: 16596359
  8. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients.
    Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5115-20 PMID: 17360338
  9. Factors associated with early remission of type I diabetes in children treated with cyclosporine.
    N Engl J Med. 1988 Mar 17;318(11):663-70 PMID: 3125434
  10. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.
    J Immunol. 2005 Sep 1;175(5):3053-9 PMID: 16116193
  11. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters.
    Nat Med. 2009 Aug;15(8):930-9 PMID: 19633656
  12. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts.
    Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13074-9 PMID: 17670937
  13. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients.
    J Clin Invest. 1993 Nov;92(5):2313-22 PMID: 8227346
  14. Cytokine related therapies for autoimmune disease.
    Curr Opin Immunol. 2008 Dec;20(6):676-81 PMID: 18940257
  15. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
    Nat Immunol. 2009 Sep;10(9):1000-7 PMID: 19633673
  16. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
    Diabetes Care. 2005 May;28(5):1068-76 PMID: 15855569
  17. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse.
    Diabetes. 2004 Oct;53(10):2581-7 PMID: 15448087
  18. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event.
    Immunity. 2009 Oct 16;31(4):643-53 PMID: 19818656
  19. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.
    J Clin Invest. 2007 Dec;117(12):3857-67 PMID: 18060033
  20. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model.
    J Exp Med. 2003 Nov 17;198(10):1527-37 PMID: 14623908
  21. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study.
    Lancet. 2008 May 24;371(9626):1777-82 PMID: 18502302
  22. Analysis of mortality in French diabetic patients from death certificates: a comparative study.
    Diabetes Metab. 1999 Nov;25(5):404-11 PMID: 10592863
  23. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.
    Nat Med. 2002 Apr;8(4):399-402 PMID: 11927947
  24. Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes.
    J Clin Invest. 2005 Jul;115(7):1879-87 PMID: 15937548
  25. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
    JAMA. 2003 Oct 22;290(16):2159-67 PMID: 14570951
  26. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.
    Lancet. 1986 Jul 19;2(8499):119-24 PMID: 2873396
  27. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.
    J Immunol. 2008 Nov 15;181(10):7350-5 PMID: 18981158
  28. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.
    J Exp Med. 2004 Jun 7;199(11):1455-65 PMID: 15184499
  29. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide.
    J Autoimmun. 1997 Jun;10(3):271-8 PMID: 9218754
  30. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors.
    Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19857-62 PMID: 19073938
  31. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.
    J Exp Med. 2001 Jun 4;193(11):1295-302 PMID: 11390436
  32. CD3-specific antibodies: a portal to the treatment of autoimmunity.
    Nat Rev Immunol. 2007 Aug;7(8):622-32 PMID: 17641665
  33. Regulatory B cells as inhibitors of immune responses and inflammation.
    Immunol Rev. 2008 Aug;224:201-14 PMID: 18759928
  34. "Infectious" transplantation tolerance.
    Science. 1993 Feb 12;259(5097):974-7 PMID: 8094901
  35. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.
    Nat Immunol. 2008 Mar;9(3):239-44 PMID: 18285775
  36. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
    Annu Rev Immunol. 1998;16:619-44 PMID: 9597144
  37. Innate immunity and intestinal microbiota in the development of Type 1 diabetes.
    Nature. 2008 Oct 23;455(7216):1109-13 PMID: 18806780
  38. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study.
    Diabetes Care. 1999 Oct;22(10):1703-7 PMID: 10526739
  39. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes.
    Diabetologia. 2009 Jun;52(6):1143-51 PMID: 19266182
  40. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
    J Immunol. 2008 Mar 1;180(5):2863-75 PMID: 18292508
  41. The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice.
    Immunol Rev. 2005 Apr;204:250-63 PMID: 15790363
  42. Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials.
    Diabetol Metab Syndr. 2009 Oct 16;1(1):19 PMID: 19835616
  43. Type 1 diabetes genes and pathways shared by humans and NOD mice.
    J Autoimmun. 2005;25 Suppl:29-33 PMID: 16257508
  44. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.
    Science. 1984 Mar 30;223(4643):1362-7 PMID: 6367043
  45. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus.
    Nat Genet. 1997 Mar;15(3):289-92 PMID: 9054944
  46. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    N Engl J Med. 2008 Oct 30;359(18):1909-20 PMID: 18843118
  47. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
    Diabetes. 2005 Jun;54(6):1763-9 PMID: 15919798
  48. Interferon-alpha as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes.
    Diabetes. 2005 Sep;54(9):2549-56 PMID: 16123342
  49. A comprehensive guide to antibody and T-cell responses in type 1 diabetes.
    Tissue Antigens. 2003 Nov;62(5):359-77 PMID: 14617043
  50. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.
    Diabetes Res. 1985 Nov;2(6):271-6 PMID: 3878262
  51. CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts.
    Eur J Immunol. 1999 Jan;29(1):156-67 PMID: 9933097
  52. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.
    Clin Exp Immunol. 2010 May;160(2):176-84 PMID: 20629979
  53. Impairment of NK cell function by NKG2D modulation in NOD mice.
    Immunity. 2003 Jan;18(1):41-51 PMID: 12530974
  54. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.
    Nat Genet. 1997 Mar;15(3):293-7 PMID: 9054945
  55. Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel.
    Diabetes Care. 2001 Apr;24(4):650-3 PMID: 11315825
  56. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
    N Engl J Med. 2009 Nov 26;361(22):2143-52 PMID: 19940299
  57. Breeding of a non-obese, diabetic strain of mice.
    Jikken Dobutsu. 1980 Jan;29(1):1-13 PMID: 6995140
  58. Genetics of type 1A diabetes.
    N Engl J Med. 2009 Apr 16;360(16):1646-54 PMID: 19369670
  59. The BB/Wor rat and the balance hypothesis of autoimmunity.
    Diabetes Metab Rev. 1996 Jul;12(2):103-9 PMID: 8877279
  60. Defective regulatory and effector T cell functions in patients with FOXP3 mutations.
    J Clin Invest. 2006 Jun;116(6):1713-22 PMID: 16741580
  61. In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression.
    Magn Reson Med. 2008 Apr;59(4):712-20 PMID: 18302224
  62. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
    Immunity. 2008 May;28(5):687-97 PMID: 18468463
  63. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
    N Engl J Med. 2002 May 30;346(22):1692-8 PMID: 12037148
  64. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    N Engl J Med. 2005 Jun 23;352(25):2598-608 PMID: 15972866
  65. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice.
    J Immunol. 1998 Oct 15;161(8):3912-8 PMID: 9780157
  66. Conserved T cell receptor alpha-chain induces insulin autoantibodies.
    Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10090-4 PMID: 18626021
  67. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.
    J Clin Invest. 2006 May;116(5):1371-81 PMID: 16628253
  68. Analysis of islet inflammation in human type 1 diabetes.
    Clin Exp Immunol. 2009 Feb;155(2):173-81 PMID: 19128359
  69. Normalization of obesity-associated insulin resistance through immunotherapy.
    Nat Med. 2009 Aug;15(8):921-9 PMID: 19633657
  70. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway.
    Immunity. 1999 Oct;11(4):463-72 PMID: 10549628
  71. Long-term risk of IDDM in first-degree relatives of patients with IDDM.
    Diabetologia. 1994 Mar;37(3):321-7 PMID: 8174848
  72. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice.
    J Clin Invest. 2009 Mar;119(3):565-72 PMID: 19188681
  73. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat.
    J Immunol. 2007 Jan 15;178(2):693-701 PMID: 17202329
  74. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.
    Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16242-7 PMID: 18852471
  75. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets.
    Immunity. 2009 Oct 16;31(4):654-64 PMID: 19818653
  76. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
    Clin Immunol. 2009 Aug;132(2):166-73 PMID: 19443276
  77. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study.
    Diabetologia. 2005 May;48(5):829-37 PMID: 15838685
  78. Dimorphic histopathology of long-standing childhood-onset diabetes.
    Diabetologia. 2010 Apr;53(4):690-8 PMID: 20062967
  79. Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done.
    J Clin Endocrinol Metab. 2006 Oct;91(10):3757-9 PMID: 17028289
  80. The NOD mouse: a model of immune dysregulation.
    Annu Rev Immunol. 2005;23:447-85 PMID: 15771578
  81. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.
    J Clin Invest. 2005 Oct;115(10):2904-13 PMID: 16167085
  82. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes.
    Science. 2009 Apr 17;324(5925):387-9 PMID: 19264985
  83. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
    Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18895-900 PMID: 19015530
  84. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families.
    Diabetes. 2008 Apr;57(4):1084-92 PMID: 18252895
  85. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes.
    JAMA. 2007 Sep 26;298(12):1420-8 PMID: 17895458
  86. AIRE in the thymus and beyond.
    Curr Opin Immunol. 2009 Dec;21(6):582-9 PMID: 19833494
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
DOI
10.1038/nature08933
Email
jbluest@diabetes.ucsf.edu
Published
2010-04-29
Pages
1293-300
Language
English
Region
England
NLM ID
0410462
PMCID
PMC4959889
Subset
IM
Grants
NIAID NIH HHS · R01 AI046643 · United States
NIAID NIH HHS · R21 AI107328 · United States
External Links
PubMed source DOI: 10.1038/nature08933 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2